JMP"Raise tgt to $9. Add'tl opportunity in Alzheimers/Schiz. Improves Sleep/Reduces caregiver burden as well."
Phase III results for pimavanserin in PDP demonstrate compelling efficacy and safety profile; reiterate Market Outperform rating and increasing price target from $5 to $9 on ACADIA Pharmaceuticals. ACADIA announced top-line Phase III results for pimavanserin in Parkinson's disease psychosis (PDP) which in our view were clearly positive both for the primary endpoint and multiple key secondary endpoints. We believe these results substantially de-risk the second Phase III trial, which we expect to begin in 1H13, and probability of approval in the U.S. and EU, as well as provide a compelling clinical profile to drive commercial adoption.
Full report at investorvillage ACAD board. Much easier to read full report